Peter Schmid, MD | Authors

Dr. Schmid Discusses the KEYNOTE-522 Trial

October 16, 2019

CancerNetwork® spoke with Dr. Peter Schmid about the KEYNOTE-522 trial.

Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

April 07, 2017

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.